Search results
Why Big-Name Biotech Regeneron Pharma Just Joined The 1,000-Club
Investor's Business Daily· 21 hours agoRivals Are Coming Dupixent is likely to be the first biologic treatment for COPD to hit the market....
Healthy Returns: Drugmakers release promising cancer drug data – and AstraZeneca wins big
CNBC· 6 days agoPatients with musculoskeletal conditions who like to stay in their pajamas received some welcome...
This startup uses overseas freelancers to help Americans find Adderall and Ozempic
Quartz· 2 days agoA startup is working to help Americans navigate ongoing shortages of highly-coveted drugs like...
Chutes & Ladders—Sanofi research head Frank Nestle says au revoir
FierceBiotech· 6 days agoPlease send the good word—or the bad—from your shop to Gabrielle Masson and it will be featured here...
European Midday Briefing: Stocks, Euro Hit by European Political Upheaval
Morningstar· 3 days agoEuropean stocks fell on Monday after European elections resulted in strong gains for right-wing Euroskeptic parties, prompting Emmanuel Macron to call a snap election in France. The main takeaways ...
Pharma Stock Roundup: LLY's CFO Departs, ABBV, AZN Drugs Get CHMP Approval
Zacks via Yahoo Finance· 6 days agoRecap of the Week’s Most Important Stories Lilly’s CFO Departs: Lilly’s executive vice president and...
10 Best ETFs To Buy and Hold for Long-Term Growth
GoBankingRates via AOL· 1 day agoIf you're a long-term investor looking to diversify your growth portfolio, there are a number of exchange-traded funds that can help you reach your...
Another Approach To Checkpoint Inhibitors: Targeting Receptors
Forbes· 3 days agoAn alternative to PD-1 targeting cancer therapies, PD-L1 checkpoint inhibitors boost antitumor...
Tirzepatide Shows Improvements in MASH Resolution, Fibrosis
Medscape· 3 days agoEncouraging phase 2 results of tirzepatide in the resolution of MASH and improvement in fibrosis...
AbbVie's (ABBV) Ovarian Cancer Therapy Meets Study Goal
Zacks· 6 days agoData from a mid-stage study shows that treatment with AbbVie's (ABBV) Elahere achieves an objective response rate of almost 52% in certain heavily pre-treated patients with ovarian cancer.